AI Engines For more Details: Perplexity Kagi Labs You
Fungal Skin Infections: Econazole nitrate is primarily used to treat fungal skin infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and fungal infections of the skin folds (intertrigo). These infections are caused by dermatophyte fungi and sometimes yeast or other fungi. Econazole nitrate works by disrupting the fungal cell membrane, leading to fungal cell death and resolution of the infection.
Yeast Infections: Econazole nitrate is also effective against yeast infections such as candidiasis, including vaginal yeast infections (vulvovaginal candidiasis) and yeast infections of the skin and mucous membranes. It inhibits the growth of Candida species by interfering with their cell membrane function.
Symptom Relief: Econazole nitrate helps relieve symptoms associated with fungal infections, including itching, burning, redness, and inflammation. By eliminating the underlying fungal infection, it promotes healing and alleviates discomfort.
Topical Application: Econazole nitrate is typically available as a cream, lotion, or solution for topical application to the affected skin or mucous membranes. It should be applied as directed by a healthcare professional, usually two to three times daily for a specified duration.
Safety and Side Effects: When used as directed, econazole nitrate is generally safe and well-tolerated. However, some individuals may experience mild side effects such as skin irritation, burning, stinging, or redness at the site of application. These side effects are usually temporary and resolve with continued use or upon discontinuation of the medication.
Adherence to Treatment: It's important for individuals prescribed econazole nitrate to adhere to the treatment regimen prescribed by their healthcare provider, even if symptoms improve before the full course of treatment is completed. Failure to complete the treatment course may result in incomplete resolution of the fungal infection and potential recurrence.
Prevention: Econazole nitrate may also be used prophylactically in individuals at risk of developing fungal infections, such as those with compromised immune systems or a history of recurrent fungal infections. However, its use for prevention should be under the guidance of a healthcare professional.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.4 | 0.5 |
| ADHD | 5 | 0.9 | 4.56 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.5 | 0.36 |
| Allergies | 7 | 3.4 | 1.06 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.5 | 1.5 | |
| Alzheimer's disease | 6.3 | 6 | 0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1 | 2.3 |
| Ankylosing spondylitis | 4.1 | 1.8 | 1.28 |
| Anorexia Nervosa | 1.6 | 2.7 | -0.69 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.3 | 2 |
| Asthma | 4.7 | 3.4 | 0.38 |
| Atherosclerosis | 1.6 | 2.4 | -0.5 |
| Atrial fibrillation | 3.5 | 2.5 | 0.4 |
| Autism | 9.3 | 9.3 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.8 | 1.8 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.9 | 2.4 | -1.67 |
| Carcinoma | 4.7 | 2.6 | 0.81 |
| Celiac Disease | 1.9 | 4.2 | -1.21 |
| Cerebral Palsy | 1.8 | 1.3 | 0.38 |
| Chronic Fatigue Syndrome | 4.7 | 6 | -0.28 |
| Chronic Kidney Disease | 4.7 | 2.9 | 0.62 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 2 | -0.33 |
| Chronic Urticaria (Hives) | 1.4 | 0.7 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.3 | 0.08 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 6.8 | 2.3 | 1.96 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 2.4 | 2.5 | -0.04 |
| COVID-19 | 10.1 | 11.3 | -0.12 |
| Crohn's Disease | 8.6 | 5.9 | 0.46 |
| Cushing's Syndrome (hypercortisolism) | 0.7 | -0.7 | |
| cystic fibrosis | 0.7 | 1.9 | -1.71 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2.8 | 1.4 | 1 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 11 | 9.2 | 0.2 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 1.5 | 0.53 |
| Endometriosis | 3 | 2.1 | 0.43 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.2 | 2.4 | 0.33 |
| erectile dysfunction | 2.5 | 0.3 | 7.33 |
| Fibromyalgia | 3.2 | 1.5 | 1.13 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 3.3 | 0.45 |
| gallstone disease (gsd) | 3.3 | 1.6 | 1.06 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 1.2 | 0.17 |
| Generalized anxiety disorder | 3.3 | 2.9 | 0.14 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2 | 1.3 | 0.54 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.8 | -1 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.4 | 1.8 | 0.89 |
| Heart Failure | 4.1 | 2.4 | 0.71 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.2 | 0.6 | 1 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
| hyperglycemia | 1.9 | 2.2 | -0.16 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.9 | 5 | -0.02 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.3 | 0.3 | 10 |
| IgA nephropathy (IgAN) | 1.9 | 3.8 | -1 |
| Inflammatory Bowel Disease | 8.2 | 8.8 | -0.07 |
| Insomnia | 1.9 | 3.5 | -0.84 |
| Intelligence | 1.4 | 0 | 0 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 7.9 | 5.8 | 0.36 |
| ischemic stroke | 3.1 | 1.7 | 0.82 |
| Liver Cirrhosis | 7.1 | 5.4 | 0.31 |
| Long COVID | 7.3 | 7.8 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.9 | 0.33 |
| ME/CFS with IBS | 0.6 | 2 | -2.33 |
| ME/CFS without IBS | 2 | 2.2 | -0.1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.7 | 1 | 0.7 |
| Metabolic Syndrome | 8 | 8.2 | -0.02 |
| Mood Disorders | 11.4 | 7.9 | 0.44 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 7.4 | 5 | 0.48 |
| Multiple system atrophy (MSA) | 1.5 | 0.7 | 1.14 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.2 | -9.67 |
| Neuropathy (all types) | 1.2 | 2.8 | -1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5 | 5.8 | -0.16 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.9 | 8.6 | 0.27 |
| obsessive-compulsive disorder | 4.8 | 3.8 | 0.26 |
| Osteoarthritis | 3.2 | 1.7 | 0.88 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 7.9 | 6.4 | 0.23 |
| Polycystic ovary syndrome | 6 | 3.2 | 0.88 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.6 | -0.33 |
| Primary sclerosing cholangitis | 2.6 | 3 | -0.15 |
| Psoriasis | 3.4 | 3.2 | 0.06 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8 | 4.2 | 0.9 |
| Rosacea | 0.7 | 1 | -0.43 |
| Schizophrenia | 7.4 | 3.6 | 1.06 |
| scoliosis | 0.4 | 0.7 | -0.75 |
| Sjögren syndrome | 2.6 | 3.1 | -0.19 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 0.5 | 2.4 |
| Stress / posttraumatic stress disorder | 3.2 | 3.3 | -0.03 |
| Systemic Lupus Erythematosus | 4.4 | 2.2 | 1 |
| Tic Disorder | 1.3 | 1.2 | 0.08 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.1 | 4 | 0.02 |
| Type 2 Diabetes | 8.7 | 8 | 0.09 |
| Ulcerative colitis | 5.1 | 6.5 | -0.27 |
| Unhealthy Ageing | 4.8 | 2.9 | 0.66 |
| Vitiligo | 2 | 1.6 | 0.25 |
